Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder
Portfolio Pulse from
Teva Pharmaceuticals and Medincell have announced that the FDA has accepted the supplemental New Drug Application for UZEDY, an extended-release injectable suspension for treating Bipolar I Disorder. This marks a significant step in expanding treatment options for BP-I in adults.
February 25, 2025 | 9:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Teva Pharmaceuticals' sNDA for UZEDY has been accepted by the FDA, potentially expanding its product offerings for Bipolar I Disorder treatment.
The FDA's acceptance of the sNDA for UZEDY is a positive regulatory development for Teva, indicating potential future revenue from an expanded product line in the mental health treatment market.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80